Litigation over a chemotherapy drug that causes permanent hair loss has attracted an unusually large number of submissions from plaintiffs attorneys hoping to be appointed lead counsel, with an informal group led by Mikal Watts competing against a slate led by Karen Barth-Menzies and Christopher Coffin.
More than 40 applications have been filed for lead roles in multidistrict litigation alleging that Paris-based Sanofi S.A. and its subsidiaries failed to warn that Taxotere could cause permanent alopecia areata, the medical term for hair loss. Louisiana Eastern District Chief Judge Kurt Engelhardt, overseeing litigation that was coordinated Oct. 4, has scheduled a hearing Thursday on who should be named lead counsel. So far, nearly 200 cases have been filed by breast cancer patients, but plaintiffs lawyers expect thousands.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
